A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

Completed

Phase 2 Results

Summary of Purpose

The purpose of this study is to determine if YM872 in combination with t-PA can reduce disability and brain damage from stroke. YM872 or placebo will be given as a continuous intravenous (iv) infusion for 24 hours. It is important that the study medication, YM872 or placebo, is administered prior to the completion of the t-PA administration. The clinical effects of YM872 in addition to t-PA will be determined...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 31 March 2006.

1 Dec 2000 16 Aug 2002 Unavailable 1 Jan 2003 1 Mar 2006 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Design

  • Allocation: Randomized
  • Masking: Double-Blind
  • Purpose: Treatment

Contacts

Not available